JP6025871B2 - ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用 - Google Patents

ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用 Download PDF

Info

Publication number
JP6025871B2
JP6025871B2 JP2014554880A JP2014554880A JP6025871B2 JP 6025871 B2 JP6025871 B2 JP 6025871B2 JP 2014554880 A JP2014554880 A JP 2014554880A JP 2014554880 A JP2014554880 A JP 2014554880A JP 6025871 B2 JP6025871 B2 JP 6025871B2
Authority
JP
Japan
Prior art keywords
leu
ala
cys
seq
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014554880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513318A (ja
JP2015513318A5 (enExample
Inventor
クリストファー ジェイ． ソアレス
クリストファー ジェイ． ソアレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015513318A publication Critical patent/JP2015513318A/ja
Publication of JP2015513318A5 publication Critical patent/JP2015513318A5/ja
Application granted granted Critical
Publication of JP6025871B2 publication Critical patent/JP6025871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014554880A 2012-01-26 2013-01-25 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用 Active JP6025871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591236P 2012-01-26 2012-01-26
US61/591,236 2012-01-26
PCT/US2013/023260 WO2013112912A1 (en) 2012-01-26 2013-01-25 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016199234A Division JP6411425B2 (ja) 2012-01-26 2016-10-07 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用

Publications (3)

Publication Number Publication Date
JP2015513318A JP2015513318A (ja) 2015-05-07
JP2015513318A5 JP2015513318A5 (enExample) 2016-03-10
JP6025871B2 true JP6025871B2 (ja) 2016-11-16

Family

ID=47682066

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014554880A Active JP6025871B2 (ja) 2012-01-26 2013-01-25 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用
JP2016199234A Active JP6411425B2 (ja) 2012-01-26 2016-10-07 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用
JP2018177504A Pending JP2019006821A (ja) 2012-01-26 2018-09-21 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016199234A Active JP6411425B2 (ja) 2012-01-26 2016-10-07 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用
JP2018177504A Pending JP2019006821A (ja) 2012-01-26 2018-09-21 ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用

Country Status (14)

Country Link
US (3) US9193776B2 (enExample)
EP (2) EP3272769B1 (enExample)
JP (3) JP6025871B2 (enExample)
KR (2) KR102052983B1 (enExample)
CN (2) CN104271596B (enExample)
AU (2) AU2013211929B2 (enExample)
CA (1) CA2861392C (enExample)
DK (1) DK2807187T3 (enExample)
ES (2) ES2641325T3 (enExample)
IL (2) IL233655A (enExample)
MX (1) MX347229B (enExample)
NO (1) NO2864579T3 (enExample)
RU (2) RU2624016C2 (enExample)
WO (1) WO2013112912A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017036308A (ja) * 2012-01-26 2017-02-16 クリストファー ジェイ． ソアレス ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6538682B2 (ja) * 2013-07-30 2019-07-03 ソアレス クリストファー ジェイ． Ｃｇｒｐアゴニストペプチド
JO3669B1 (ar) 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
TW201734035A (zh) * 2016-01-04 2017-10-01 艾得珮索拉公司 胜肽類似物
ES2965087T3 (es) 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
CA2967616A1 (en) * 2016-09-19 2018-03-19 The Governors Of The University Of Alberta Brain penetrant amylin receptor based peptides for alzheimer's disease
CN111479823A (zh) * 2017-11-06 2020-07-31 奥克兰联合服务有限公司 肽缀合物cgrp受体拮抗剂及其制备方法和用途
JP7214104B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (enExample) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993025221A1 (en) 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
AU2731797A (en) 1996-04-15 1997-11-19 University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP2233497A3 (en) * 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1853627A2 (en) * 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
CN101208098A (zh) * 2005-03-31 2008-06-25 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
EP1954313A1 (en) * 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
JP5123197B2 (ja) * 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
CA2705708A1 (en) 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
US20140249076A1 (en) 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
MX347229B (es) 2012-01-26 2017-04-19 Christopher J Soares Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
EA025358B1 (ru) 2012-02-27 2016-12-30 Бристол-Майерс Сквибб Компани N-(5S,6S,9R)-5-АМИНО-6-(2,3-ДИФТОРФЕНИЛ)-6,7,8,9-ТЕТРАГИДРО-5H-ЦИКЛОГЕПТА[b]ПИРИДИН-9-ИЛ-4-(2-ОКСО-2,3-ДИГИДРО-1H-ИМИДАЗО[4,5-b]ПИРИДИН-1-ИЛ)ПИПЕРИДИН-1-КАРБОКСИЛАТНАЯ СОЛЬ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017036308A (ja) * 2012-01-26 2017-02-16 クリストファー ジェイ． ソアレス ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用

Also Published As

Publication number Publication date
ES2819825T3 (es) 2021-04-19
WO2013112912A1 (en) 2013-08-01
CN104271596A (zh) 2015-01-07
EP3272769A1 (en) 2018-01-24
CN108997490A (zh) 2018-12-14
EP2807187A1 (en) 2014-12-03
JP2017036308A (ja) 2017-02-16
ES2641325T3 (es) 2017-11-08
US20140329752A1 (en) 2014-11-06
KR101855242B1 (ko) 2018-05-09
JP2015513318A (ja) 2015-05-07
KR20170071613A (ko) 2017-06-23
NO2864579T3 (enExample) 2018-01-20
US10370425B2 (en) 2019-08-06
IL233655A (en) 2017-06-29
EP2807187B1 (en) 2017-07-26
US20170204155A1 (en) 2017-07-20
RU2017119773A3 (enExample) 2020-11-18
AU2013211929B2 (en) 2016-05-26
AU2016205801A1 (en) 2016-08-04
AU2013211929A1 (en) 2014-09-11
EP3272769B1 (en) 2020-06-17
MX2014008960A (es) 2015-01-16
RU2742826C2 (ru) 2021-02-11
IL233655A0 (en) 2014-08-31
US20160145315A1 (en) 2016-05-26
BR112014018284A2 (pt) 2017-07-04
RU2014131605A (ru) 2016-03-20
IL252555A0 (en) 2017-07-31
KR20140132342A (ko) 2014-11-17
IL252555B (en) 2020-06-30
RU2624016C2 (ru) 2017-06-30
KR102052983B1 (ko) 2019-12-06
JP6411425B2 (ja) 2018-10-24
CA2861392C (en) 2021-08-17
MX347229B (es) 2017-04-19
RU2017119773A (ru) 2018-12-06
US9193776B2 (en) 2015-11-24
HK1201068A1 (en) 2015-08-21
DK2807187T3 (en) 2017-09-11
HK1249915A1 (en) 2018-11-16
CN104271596B (zh) 2018-09-18
JP2019006821A (ja) 2019-01-17
CA2861392A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
JP6411425B2 (ja) ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用
AU2019202918B2 (en) Agonist of spexin-based galanin type 2 receptor and use thereof
WO1993012139A1 (en) A novel molecule which inhibits neuropeptide tyrosine biological function
KR20010085847A (ko) 펩티드 유도체
JP2019504119A (ja) ペプチド類似体
HK1249915B (en) Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
BR112014018284B1 (pt) Antagonista de peptídeo relacionado ao gene da calcitonina, composições farmacêuticas e uso dos mesmos
HK1201068B (en) Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
JP4760377B2 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
JPWO2005065703A1 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
AU3250693A (en) A novel molecule which inhibits neuropeptide tyrosine biological function
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160122

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160122

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161011

R150 Certificate of patent or registration of utility model

Ref document number: 6025871

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250